Phase 1 study

Recruiting Phase 1

Sources: ClinicalTrials.gov Checked: 11 October 2026 Not medical advice

This trial at a glance

Status Recruiting
Phase Phase 1
Sponsor Akeso
Registry number NCT06929663
Started 2 July 2025 Today 16 October 2026 Estimated completion 5 November 2026

Where this trial is running

Trial sites and the status recorded for each
SiteCityState or countryStatus at this site
Scientia Clinical Research Sydney NSW Recruiting

voxsanity.com.au · trial sites from public registries · registry record synced 11 October 2026 · not medical advice

Who can join

Age 18 Years to 75 Years
Sex Anyone, regardless of sex
Healthy volunteers Not accepted
Enrolment target 48

The official eligibility criteria

Registry text, reproduced exactly. These are the words the trial's sponsor published on ClinicalTrials.gov. They have not been edited, shortened or rewritten, and they are written for researchers rather than for patients.

Inclusion Criteria:

1. Be able to understand and voluntarily sign the written informed consent form.

2. Aged of ≥ 18 years and ≤75 years.

3. ECOG PS 0 or 1.

4. The expected lifespan is ≥3 months.

5. Histologically-confirmed unresectable advanced solid tumors with disease progression or intolerance to standard treatment or no standard treatment available.

6. At least one measurable lesion according to RECIST v1.1.

7. Have sufficient organ function.

8. Females subjects must not be pregnant at screening or have evidence of non-childbearing potential. Agree to use medically accepted methods of contraception

Exclusion Criteria:

1. Having other active malignancies within 3 years.

2. Currently participating in another interventional clinical study.

3. Presence of active metastases to the central nervous system. For patients with asymptomatic brain metastasis or stable symptoms after treatment can be included.

4. Having received any treatment targeting Trop2 or Nectin4 or any treatment with topoisomerase I inhibitor agents.

5. Having received systemic anti-tumor treatment within 4 weeks or 1 cycle interval of the regimen or major surgical operations within 4 weeks before the first administration.

6. Toxicity of previous antineoplastic therapy has not resolved to NCI CTCAE 5.0 grade 1 or lower.

7. Subjects with clinically significant cardiovascular or cerebrovascular diseases or risks.

8. Subjects with active autoimmune diseases requiring systemic treatment within 2 years.

9. Known active infection requiring antibodies treatment within 2 weeks, or severe infection within 4 weeks prior to the first dose.

10. Known to be positive for HIV and other infections.

11. Previous history of severe hypersensitivity reactions.

12. Live attenuated vaccines were received within 4 weeks.

13. Subjects with a history of mental illness and incapacitated or limited capacity.

14. Any disease or condition that, in the opinion of the investigator, would compromise subject safety or interfere with study assessments.

Dates on the record

Started 2 July 2025
Estimated completion 5 November 2026
Registry last updated 17 July 2025
Checked by Voxsanity 11 October 2026

Results, publications and the official record

Sources and dates

  • ClinicalTrials.gov – the record this page reformats
  • ClinicalTrials.gov processing date: 17 July 2025.
  • This page last checked by Voxsanity: 11 October 2026.

Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.

Not medical advice.

Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Letter for your doctor

A one-page summary of this trial to print or email to your GP. It carries the registry's own record of the trial and its eligibility criteria, and nothing Voxsanity has written about whether it suits you.